Two-year outcomes after transcatheter or surgical aortic-valve replacement.

By S. Kodali, Mathew R. Williams, Craig R. Smith, L. Svensson, J. Webb, R. Makkar, G. Fontana, T. Dewey, V. Thourani, A. Pichard and 15 more. New England Journal of Medicine, 2012

2,200 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Epidemiology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/6220ef28b0820b3b1def0893596a92ad5e0f63f4

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. Catherine M. Otto
2. Rick A. Nishimura
3. R. Bonow
4. P. O'Gara
5. Thoralf M. Sundt
6. John Erwin
7. Annemarie Thompson
8. M. Mack

In Epidemiology

1. Rick A. Nishimura
2. Catherine M. Otto
3. P. O'Gara
4. R. Bonow
5. John Erwin
6. Thoralf M. Sundt
7. Annemarie Thompson
8. M. Mack

Citations in the corpus

• 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. (2017, background): “III: No Benefit B TAVR is not recommended in patients in whom existing comorbidities would preclude the expected benefit from correction of AS (61).”
• Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. (2012, background): “There is growing evidence suggesting a significant association of post-procedural paravalvular aortic regurgitation (AR) with shortand long-term mortality [48, 49].”
• Incidence, predictors, and outcomes of aortic regurgitation after transcatheter aortic valve replacement: meta-analysis and systematic review of literature. (2013, neutral): “*Different valve, n 2; nonconsecutive patients, n 8; 30 patients, n 19; i AR aortic regurgitation; TAVI transcatheter aortic valve implantation; TAVR lications had 2 randomized comparisons (10) (Online Ref.”
• The worldwide environment of cardiovascular disease: prevalence, diagnosis, therapy, and policy issues: a report from the American College of Cardiology. (2012, background): “Laslett etal. lar regurgitation remained higher in the TAVR group with adverse prognostic significance (101).”
• 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. (2017, background): “III: No Benefit B TAVR is not recommended in patients in whom existing comorbidities would preclude the expected benefit from correction of AS (61).”